Verition Fund Management LLC acquired a new position in shares of Cerus Co. (NASDAQ:CERS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,742 shares of the biotechnology company’s stock, valued at approximately $95,000.
Other institutional investors have also recently bought and sold shares of the company. HighTower Advisors LLC raised its stake in shares of Cerus by 18.2% during the 4th quarter. HighTower Advisors LLC now owns 15,365 shares of the biotechnology company’s stock worth $107,000 after buying an additional 2,365 shares during the last quarter. Procyon Private Wealth Partners LLC raised its position in Cerus by 16.0% during the fourth quarter. Procyon Private Wealth Partners LLC now owns 18,274 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 2,520 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Cerus by 3.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 98,573 shares of the biotechnology company’s stock valued at $682,000 after purchasing an additional 3,610 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Cerus by 39.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 12,840 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 3,650 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Cerus by 1.1% during the 4th quarter. Swiss National Bank now owns 375,700 shares of the biotechnology company’s stock worth $2,600,000 after purchasing an additional 4,000 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.
In related news, SVP Carol Moore sold 29,331 shares of the firm’s stock in a transaction on Monday, March 15th. The stock was sold at an average price of $6.38, for a total transaction of $187,131.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO William Mariner Greenman sold 156,407 shares of Cerus stock in a transaction on Monday, March 15th. The stock was sold at an average price of $6.38, for a total transaction of $997,876.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 254,787 shares of company stock valued at $1,638,704. Insiders own 6.49% of the company’s stock.
Separately, Zacks Investment Research downgraded Cerus from a “hold” rating to a “sell” rating in a research report on Friday, February 19th.
Shares of NASDAQ CERS opened at $5.91 on Thursday. The firm has a market cap of $994.18 million, a P/E ratio of -15.15 and a beta of 1.37. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.42 and a current ratio of 3.84. Cerus Co. has a 1 year low of $4.84 and a 1 year high of $8.87. The firm’s 50 day moving average price is $6.35 and its 200 day moving average price is $6.65.
Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, February 25th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $28.20 million during the quarter, compared to analyst estimates of $28.20 million. Cerus had a negative net margin of 73.72% and a negative return on equity of 63.47%. As a group, equities analysts predict that Cerus Co. will post -0.37 EPS for the current year.
Cerus Company Profile
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E.
Further Reading: Stock Market – What is a circuit breaker?
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.